Determining the role of Circulating Tumour Cells in promoting metastasis and treatment resistance in Small Cell Lung Cancer using preclinical in vivo models and novel CTC approaches

Closing date: 17/11/2025

Non-Clinical Studentship Project: Determining the role of Circulating Tumour Cells in promoting metastasis and treatment resistance in Small Cell Lung Cancer using preclinical in vivo models and novel CTC approaches

Lead Supervisors: Dr Dominic Rothwell
Co-Supervisors: Dr Kathryn Simpson, Prof. Caroline Dive, Prof. Fiona Blackhall

Applications Deadline: 12:00pm Monday 17th November 2025
Interviews: Week commencing 12th January 2026
Start date: September 2026

Project Keywords: CTC, SCLC, metastasis
Research Opportunity: Non-Clinical Studentship leading to the award of PhD

Project Outline

Metastases are the predominant cause of cancer-related deaths yet remain difficult to study due to their spatial and temporally sporadic occurrence. This unmet clinical need is starkly exemplified in Small Cell Lung Cancer (SCLC), an incurable neuroendocrine (NE) carcinoma. Underpinning rapid disease evolution, SCLC is one of the most metastatic cancers where >80% patients present with incurable metastatic disease, frequently in the liver and the brain.

CTCs are highly abundant in SCLC patients, linked to poor prognosis and likely contributing to the extensive metastatic burden. Despite all patients receiving chemotherapy combined with immunotherapy, with no stratification, phenotypic heterogeneity is now extensively documented in SCLC.

This is underpinned by molecular plasticity at the transcriptomic and epigenetic levels that contributes to rapid evolution and disease resistance. SCLC biopsy is difficult and repeat biopsy is almost never achievable, thus tracking evolution over time is challenging. Therefore, we developed >65 CTC-derived patient explant models (CDX) in immunodeficient mice and show these to be faithful models of the donor’s disease, including tractable metastasis to multiple organs commonly observed in patients.

Using our in vivo resection protocol, combined with genetic manipulation of CDX cells enabling reporter-gene expression and live imaging, combined with CTC identification and capture, this project now seeks to bridge the gap in understanding the metastatic journey between established tumours and their subsequent metastases. By isolating and molecularly profiling CTCs using state-of-the-art methods developed in NBC we aim to understand how CTCs reflect the heterogeneity and plasticity of SCLC.

This project builds on substantial expertise in NBC and aims to translate findings from preclinical models into patient samples in collaboration with clinical partners at the Christie hospital. By furthering our understanding of the role of CTCs in promoting its aggressive characteristics, we aim to ultimately develop novel therapies and biomarkers for better patient outcomes.

Applications for this project are now open. Please complete your application on The University of Manchester website.

About Dr Dominic Rothwell (project Lead Supervisor)

Dr Dominic G. Rothwell. Deputy Director, CR-UK National Biomarker Centre, Rare Cells Team Lead, University of Manchester, UK.

After obtaining a BSc(Hon) in Applied Genetics from the University of Liverpool I studied for my DPhil with Professor Ian Hickson at the Weatherall Institute, University of Oxford investigating the functional role of DNA repair genes. After this I moved into translational research, initially looking for molecular markers in multiple myeloma then immunotherapy trials. In 2011 I joined the Nucleic Acid Biomarker (NAB) team of Professor Caroline Dive at the CRUK Manchester Institute and began my current research interest in the molecular analysis of liquid biomarkers for use in precision oncology. This work focusses on utilising multiple analytes, including plasma proteins, circulating free DNA and circulating tumour cells to enable the molecular characterisation of tumours at the genetic, epigenetic and transcriptional level. I took over as Team Leader of NAB in November 2019 and became Deputy Director of the CR-UK National Biomarker Centre in November 2022 where I lead a wide range of biomarker-focussed projects ranging from early detection, diagnosis, MRD through to investigating mechanisms of resistance.

Dominic Rothwell headshot

Key information

Before submitting an application, please ensure you have read the information below about the funding arrangements and eligibility for Non-Clinical Studentships.

We also encourage you to get in contact with the lead supervisor to discuss the project and any particulars.

Further information is available on the Non-Clinical PhD Studentships webpage.

Fees and Funding
Eligibility
How to apply
Applications Timelines

Useful Links

Submit your application

Interested in applying for this opportunity? Submit your application on The University of Manchester application portal.

Non-Clinical PhD Studentships

Learn more about our Non-Clinical PhD Studentships.

Get in Touch

Contact Dr Yasmin Noori Jenaghard, Postgraduate Programme Manager.

Researcher Stories

Read first-hand experiences of from cancer scientists from across Manchester.

Why Manchester?

Find out why postgraduate students choose to study in Manchester.

A Day in the Life of a Non-Clinical PhD Student

Watch our short video to see what it's like to be a Non-Clinical PhD student in Manchester.